Chronic inotropic therapy in end-stage heart failure

American Heart Journal

Volumn 152, Issue 6, 2006, Pages 1096.e1-1096.e8

  Hauptman, Paul J ^a   Mikolajczak, Peter ^a   George, Anil ^a   Mohr, Clinton J ^a   Hoover, Robert ^b   Swindle, Jason ^a   Schnitzler, Mark A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CIGNA Healthcare Medicare Administration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; INOTROPIC AGENT; MILRINONE; NITRATE; SPIRONOLACTONE;

AGE DISTRIBUTION; AGED; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DATA ANALYSIS; DRUG COST; DRUG INTERMITTENT THERAPY; FEMALE; HEALTH CARE COST; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OUTPATIENT; PRIORITY JOURNAL; REIMBURSEMENT; SURVIVAL RATE; TREATMENT DURATION;

EID: 33845217359     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.08.003     Document Type: Article

References (39)

1. Gillum R.F. Epidemiology of heart failure in the United States. Am Heart J 126 (1993) 1042-1047
2. Croft J.B., Giles W.H., Pollard R.A., et al. Heart failure survival among older adults in the United States. Arch Int Med 159 (1999) 505-510
3. Ho K.K.L., Anderson K.M., Kannel W.B., et al. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 88 (1993) 107-115
4. Brown D.W., Haldeman G.A., Croft J.B., et al. Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000. Am Heart J 150 (2005) 448-458
5. AHA Statistical Update. Heart Disease and Stroke Statistics-2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
6. Krumholz H.M., Parent E.M., Tu N., et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 157 (1997) 99-104
7. Baker D.W., Einstadter D., Thomas C., et al. Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991-1997. Am Heart J 146 (2003) 258-264
8. Vinson J.M., Rich M.W., Sperry J.C., et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 38 (1990) 1290-1295
9. Colucci W.S., Wright R.F., Jaski B.E., et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 73 3 Pt 2 (1986) III175-III183
10. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. American College of Cardiology Web Site. Available at:. http://www.acc.org/clinical/guidelines/failure//index.pdf [Accessed January 31, 2006]
11. Bayram M., De Luca L., Massie B.M., et al. Reassessment of dobutamine, dopamine and milrinone in the management of acute heart failure syndromes. Am J Cardiol 96 Suppl (2005) 47G-58G
12. Ewy G.A. Inotropic infusions for chronic congestive heart failure: medical miracles or misguided medicinals?. J Am Coll Cardiol 33 (1999) 572-575
13. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray?. J Am Coll Cardiol 22 Suppl A (1993) 119A-126A
14. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 (1991) 1468-1475
15. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 339 (1998) 1810-1816
16. www.cignagovernmentservices.com/dmerc/lmrp_lcd/eip_fed.html, accessed December 26, 2005
17. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 3 (2003) 590-598
18. Shrout P.E., and Fleiss J.L. Intra-class correlations: uses in assessing rater reliability. Psychol Bull 86 (1979) 420-428
19. Rapezzi C., Bracchetti G., Branzi A., et al. The case against outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant 8S (2000) S58-S63
20. Felker G.M., and O'Connor C.M. Between Scylla and Charybdis: the choice of inotropic agent for decompensated heart failure. Am Heart J 142 (2001) 932-933
21. Felker G.M., and O'Connor C.M. Inotropic therapy for heart failure: an evidence based approach. Am Heart J 142 (2001) 393-401
22. O'Connor C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (2000) 78-86
23. Haldeman G.A., Croft J.B., Giles W.H., et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 137 (1999) 352-360
24. Popovic J.R., and Kozak L.J. National Hospital Discharge Survey: annual summary, 1998. Vital and health statistics. Series 13. No. 148 (2000), Government Printing Office, Washington (DC) [DHHS publication no. (PHS) 2000-1719]
25. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
26. Rose E., Gelijns A., Moskowitz A., et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
27. Stevenson L.W., Miller L.W., Desvigne-Nickens P., et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH. Circulation 110 (2004) 975-981
28. Wilson J.R., Smith J.S., Dahle K.L., et al. Impact of home health care on health care costs and hospitalization frequency in patients with heart failure. Am J Cardiol 83 (1999) 615-617
29. Applefeld M.M., Newman K.A., Sutton F.J., et al. Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients. Am Heart J 114 (1987) 589-595
30. Upadya S., Lee F.A., Saldarriaga C., et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant 23 (2004) 466-472
31. Aranda J.M., Schofield R.S., Pauly D.F., et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am H J 145 (2003) 324-329
32. Marius-Nunez A.L., Heaney L., Fernandez R.N., et al. Intermittent inotropic therapy in an outpatient setting: a cost effective therapeutic modality in patients with refractory heart failure. Am Heart J 132 (1996) 805-808
33. Elis A., Bental T., Kimchi O., et al. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized double blind placebo controlled study. Clin Pharmacol Ther 63 (1998) 682-685
34. Oliva F., Latini R., Politi A., et al. Intermittent 6-month low dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart (1999) 247-253
35. Cuffe M., Califf R.M., Adams Jr. K.F., et al. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
36. Harjai K.J., Mehra M.R., Ventura H.O., et al. Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes. Chest 112 (1997) 1298-1303
37. Hershberger R.E., Nauman D., Walker T.L., et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory end stage heart failure. J Card Fail 9 (2003) 188-191
38. Rich M.W., and Shore B.L. Dobutamine for patients with end-stage heart failure in a hospice program. J Palliative Med 6 (2003) 93-97
39. In: Cardinale V.A. (Ed). Drug topics redbook (1996-2002), Medical Economics Co, Inc.,, Montvale (NJ) 217-315